Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Total Liabilities data on file, last reported at $2.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 44.99% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (down 44.99% YoY), and the FY2025 full-year result was $2.9 million, down 44.99% from the prior year.
• Total Liabilities grew to $2.9 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $25.9 million in Q1 2021 to a low of $1.1 million in Q2 2024.
• A 5-year average of $3.2 million and a median of $1.8 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 5741.12% in 2021 and sank 95.76% in 2022, its largest moves.
• Tracing MNPR's Total Liabilities over 5 years: stood at $1.6 million in 2021, then soared by 98.5% to $3.1 million in 2022, then plunged by 43.98% to $1.8 million in 2023, then soared by 198.98% to $5.3 million in 2024, then sank by 44.99% to $2.9 million in 2025.
• Business Quant data shows MNPR's Total Liabilities at $2.9 million in Q4 2025, $2.6 million in Q3 2025, and $1.7 million in Q2 2025.